Clinical Trial Update: Effects of Ergocalciferol on Erythropoetin Stimulating Agent Dose [NA]

View source ↗

Summary

A terminated trial evaluated whether ergocalciferol could reduce ESA (erythropoiesis-stimulating agent) dose in chronic kidney disease stages 3-5. Results were …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease

Drugs mentioned

• ergocalciferol (ergocalciferol)

Snippet

Sponsor: Kaiser Permanente | Conditions: Chronic Kidney Disease Stages 3-5 | NA | Status: TERMINATED | Results posted: 2012-09-20